Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Regeneron Ventures is a health care venture capital fund launched in April 2024, headquartered in Greenwich, Connecticut. The fund operates independently from its sole limited partner, Regeneron Pharmaceuticals, Inc., which has a market capitalization exceeding $100 billion. Regeneron Ventures shares a patient-centric and science-based mission, focusing on investments that aim to improve health outcomes.
The fund has a total commitment of $500 million over five years, translating to an annual investment capacity of $100 million. Regeneron Ventures is structured as an independent general partner (GP) with a single limited partner (LP) model. This structure allows the fund to maintain a focused investment strategy while benefiting from the extensive resources and expertise of Regeneron Pharmaceuticals.
Since its inception, Regeneron Ventures has positioned itself as a key player in the health care investment space, particularly in biotechnology and medical devices. The firm is actively deploying capital and is expected to build a diverse portfolio of innovative health care companies.
Regeneron Ventures invests broadly across the health care sector, with a strong emphasis on biotechnology, medical devices, tools, and enabling technologies. The fund's investment strategy is stage-agnostic, allowing it to consider opportunities from seed stage through late-stage investments. This flexibility enables the firm to engage with a wide range of companies that are focused on health improvement.
Investment decisions at Regeneron Ventures prioritize the quality of the people, science, and data involved in potential investments. The firm is particularly open to breakthrough innovations, demonstrating a willingness to tolerate the inherent risks and uncertainties associated with pioneering health technologies. This approach aligns with their mission to support companies that are dedicated to improving health outcomes.
Jay S. Markowitz, M.D. - Co-GP. Jay has a background as a Senior Partner at ARCH Venture Partners and served as Senior Vice President at Regeneron from 2017 to 2020. He has founded three companies during his tenure at ARCH and started his career in medicine.
Michael Aberman, M.D. - Co-GP. Michael previously held the position of Senior Vice President of Investor Relations and Strategy at Regeneron. He is the former CEO and Co-founder of XenImmune Therapeutics and Quentis Therapeutics, both in the biotech sector. He also began his career in medicine.
Startups looking to pitch to Regeneron Ventures should submit their proposals through the official website at regeneronventures.com. It is recommended to include a comprehensive deck that outlines the team, the science behind the product, and supporting data.
Response times may vary, but founders should expect a thorough review process given the fund's commitment to quality investments. Warm introductions are preferred, as they can facilitate a more favorable evaluation of the pitch.
In April 2024, Regeneron Ventures officially launched with a commitment of $500 million to invest in health care innovations. The fund is actively deploying capital and is expected to build a diverse portfolio of companies focused on biotechnology and medical devices.
As of the latest updates, specific portfolio investments have not yet been publicly announced, but the fund is recognized for its strong backing by Regeneron Pharmaceuticals, enhancing its credibility in the venture capital space.
What are Regeneron Ventures' investment criteria?
Regeneron Ventures focuses on investing in companies within the health care sector, particularly in biotechnology and medical devices. The fund emphasizes the quality of the people, science, and data involved in potential investments, and is open to breakthrough innovations.
How can startups apply or pitch to Regeneron Ventures?
Startups interested in pitching to Regeneron Ventures can do so through their website at regeneronventures.com. It is advisable to include detailed information about the team, the science behind the product, and any relevant data supporting the innovation.
What makes Regeneron Ventures different from other venture capital firms?
Regeneron Ventures operates independently while benefiting from the extensive resources and expertise of Regeneron Pharmaceuticals. This unique structure allows the fund to provide strategic guidance and support to portfolio companies, enhancing their potential for success.
What is the geographic scope of Regeneron Ventures?
The firm primarily invests in North America, focusing on health care innovations that can significantly impact patient outcomes.
What is the fund size and check size range?
Regeneron Ventures has a total fund size of $500 million, with an annual commitment of $100 million. Specific check sizes for individual investments have not been publicly disclosed.
What kind of post-investment involvement does Regeneron Ventures have?
Regeneron Ventures aims to provide strategic guidance and leverage the resources of Regeneron Pharmaceuticals to help portfolio companies turn great ideas into successful products. This includes operational support and access to a network of industry experts.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.